Healthcare providers across Canada will soon be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.®
This partnership integrates MyMeds&Me’s validated safety data capture solution into Auxita, enabling healthcare providers, patient support programs and pharmaceutical companies to capture and manage data more efficiently.
MyMeds&Me® is a global organization that provides an established end-to-end pharmacovigilance solution to simplify adverse event and product quality data capture. Its drug safety platform, Reportum, is used by pharmaceutical companies around the world to standardize data capture, streamline downstream processes and provide real-time access to complete, relevant safety information.
“Auxita is pleased to expand our service offering to enhance the management of safety data, captured at source from healthcare providers,” says Matt Cahill, CEO of Auxita. “Through our EMR and EHR-integrated platform, we provide an intuitive and standardized digital process to collect data and manage the flow of information throughout the patient journey. This partnership will offer patient support programs real-time access and enhanced visibility to key safety information.”
“Robust pharmacovigilance relies on a comprehensive body of complete, structured, and timely data. Therefore, it is critical that we make safety reporting really easy and intuitive for both physicians and patient support program staff whether in the office or out in the field” says Dr. Andrew Rut, CEO and founder of MyMeds&Me. “Our partnership with Auxita enables efficient capture of standardized information for our clients so they can accelerate safety insights.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.